Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Pediatric Non-Infectious Uveitis
NCT07913750Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Open-label trial of adalimumab in noninfectious uveitis (NIU) (2 cohorts), sponsored by Samsung Medical Center. Primary endpoints: Treatment Failure Rate at 12 months and Medically Important Infections at 12 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on NCT07913750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07913750.